Q-omics provides the consensus-scored DUSP22 profile across patient tissues and cancer cell-line models. DUSP22 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, DUSP22 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, DUSP22 protein abundance shows 26,814 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, BLCA, and LUAD as cancer lineages where DUSP22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUSP22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUSP22 survival associations across molecular data types. DUSP22 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUSP22 RNA expression–survival associations across cancer types. High DUSP22 expression shows unfavorable associations in LUSC and KICH, but favorable associations in MESO, KIRC, UVM and UCS. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for DUSP22 RNA expression.
This table summarizes DUSP22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DUSP22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUSP22 shows lower tumor expression in BLCA, LUAD, KICH, THCA and LUSC and higher tumor expression in LIHC. The BLCA box plot shows higher DUSP22 RNA expression in normal versus tumor tissue (log2 FC = −0.831, t-test p < 0.001).
This table shows molecular features associated with DUSP22 in patient tissues and cancer cell lines. In patient samples, DUSP22 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DUSP22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
